TEVA PHARMACEUTICALS USA, INC.
Clinical Trials
0
Trial Phases
0 Phases
Drug Approvals
235
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- 5
- 24
- Next
Clinical Trials
News
Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer
Alvotech, a global biosimilar medicines company, has appointed Linda Jónsdóttir as Chief Financial Officer, bringing 15 years of senior leadership experience from Marel food processing technology company.
Alvotech Acquires Swiss Packaging Specialist Ivers-Lee to Expand Biosimilar Manufacturing Capacity
Alvotech has acquired Ivers-Lee Group, a Swiss family-owned pharmaceutical packaging company founded in 1947, to expand its assembly and packaging capabilities ahead of three new biosimilar launches in 2025.
Five-Year SEQUOIA Data Confirms Zanubrutinib's Long-Term Efficacy in High-Risk CLL/SLL Patients
Five-year follow-up data from the SEQUOIA study demonstrates zanubrutinib's sustained efficacy in treatment-naive chronic lymphocytic leukemia and small lymphocytic lymphoma patients with del(17p).
Alvotech Expands European Presence with Successful Nasdaq Stockholm Listing
Alvotech's Swedish Depository Receipts (SDRs) offering was multiple times oversubscribed, attracting over 3,000 new shareholders and raising approximately SEK 39 million.
FDA Approves 25 First-Time Generic Drugs in First Half of 2025, Expanding Access to Critical Therapies
The FDA approved 25 first-time generic drugs in the first six months of 2025, including generics for critical medications treating HIV, cancer, and neurological conditions.
FDA Accepts Teva's Application for AJOVY in Pediatric Migraine Prevention, Potentially First CGRP Antagonist for Children
The FDA has accepted Teva Pharmaceuticals' supplemental Biologics License Application for AJOVY (fremanezumab) to expand its indication to include prevention of episodic migraine in children and adolescents aged 6-17 years weighing at least 45 kg.
Fremanezumab Demonstrates Long-Term Efficacy in Migraine Prevention Across Multiple Real-World Studies
The phase 4 PEARL study involving 1,140 patients confirmed fremanezumab's long-term effectiveness, with 66% of episodic migraine patients and 51.6% of chronic migraine patients achieving at least 50% reduction in monthly migraine days over 24 months.
Patent Strategies for GLP-1 Receptor Agonists: Extending Drug Lifecycles Through Novel Applications
GLP-1 receptor agonists like semaglutide, originally approved for diabetes (Ozempic), have expanded to weight management (Wegovy) and show potential in treating neurocognitive disorders and reducing alcohol cravings.
Ten Adalimumab Biosimilars Now Available in US Market Following Latest FDA Approval
The FDA has approved ten adalimumab biosimilars, with Simlandi (adalimumab-ryvk) becoming the latest addition in February 2024, expanding treatment options for various autoimmune conditions.
Federal Circuit Rules Against Teva's Orange Book Patent Listings for ProAir HFA Inhaler
The U.S. District Court ordered Teva Pharmaceuticals to remove its ProAir HFA inhaler device patents from the FDA's Orange Book, ruling they don't meet statutory listing requirements.